XML 61 R46.htm IDEA: XBRL DOCUMENT v3.25.4
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Years Ended December 31,
202520242023
Total revenues$3,221,253 $2,853,915 $2,419,226 
Less:
Cost of sales717,442 580,235 532,062 
R&D expenses
Research and early pipeline383,705 434,023 393,078 
Later-stage clinical programs308,334 27,581 62,604 
Marketed products229,891 285,580 291,091 
SG&A expenses
S&M expenses
530,156 476,739 488,442 
G&A expenses
622,861 532,286 403,964 
Other segment expense, net (1)
79,963 90,612 80,340 
Net income$348,901 $426,859 $167,645 
(1)Other segment expense, net, during the years ended December 31, 2025, 2024 and 2023 included Intangible Asset Amortization, Interest Income and Expense, Other Income (Expense), Net and Provision for Income Taxes. The year ended December 31, 2024 also included Gain on Sale of Nonfinancial Assets.
Schedule of Total Revenues and Disaggregates Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Years Ended December 31,
202520242023
VOXZOGO$926,923 $735,092 $469,881 
Enzyme Therapies:
VIMIZIM792,051 739,784 701,053 
NAGLAZYME485,400 479,584 420,292 
PALYNZIQ433,310 355,047 303,919 
ALDURAZYME208,508 183,887 131,248 
BRINEURA186,397 169,083 161,889 
KUVAN99,530 120,902 180,767 
ROCTAVIAN35,640 26,066 3,489 
Total net product revenues3,167,759 2,809,445 2,372,538 
Royalty and other revenues53,494 44,470 46,688 
Total revenues$3,221,253 $2,853,915 $2,419,226 
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Years Ended December 31,
202520242023
United States$1,104,973 $924,810 $771,314 
Europe874,331 829,031 669,331 
Latin America435,478 378,084 332,437 
Rest of world544,469 493,633 468,208 
Total net product revenues marketed by the Company2,959,251 2,625,558 2,241,290 
ALDURAZYME net product revenues marketed by Sanofi208,508 183,887 131,248 
Total net product revenues$3,167,759 $2,809,445 $2,372,538 
Schedule of Total Net Product Revenues Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Years Ended December 31,
202520242023
Customer A14 %13 %14 %
Customer B12 %12 %12 %
Customer C11 %10 %10 %
Total37 %35 %36 %
Schedule of Long-Lived Assets by Geographic Region
Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.
December 31,
20252024
Long-lived assets by geography:
United States$639,669 $755,069 
Ireland331,287 308,123 
Rest of world20,841 13,600 
Total long-lived assets$991,797 $1,076,792